By Sabela Ojea

 

AstraZeneca PLC said Monday that the Calquence drug-inhibitor showed improvements in atrial fibrillation when compared with ibrutinib in previously treated adult patients with chronic lymphocytic leukemia.

The pharmaceutical giant said Calquence also proved to give favorable tolerability at four years.

The company said these final results of Calquence come from the head-to-head elevate-rr phase 3 trial.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

June 07, 2021 02:30 ET (06:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AstraZeneca Charts.